Zynerba Pharmaceuticals, Inc. Equity-NMS: ZYNE

Healthcare

Drug Manufacturers - Specialty & Generic

Buy/Sell an entire stock
or a fraction.
Powered by Vested Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly
Loading, Please wait...
Previous close :$1.3

Compare with Other Stocks

Stocks Price 1D PE Market Cap
Zynerba Pharmaceuticals, Inc. $1.3 0% - NaN

Frequently Asked Questions

What is the share price of Zynerba Pharmaceuticals, Inc. today?

Zynerba Pharmaceuticals, Inc. (ZYNE) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). It is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. It is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). It uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).